Developments Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that... June 5, 2024